Related Experiment Videos
Modulation of CD14 expression on human granulocytes by a bacterial product "Cantastim" derived from Pseudomonas
D L Radu1, A Dolganiuc, N Istrate
1Cantacuzino Institute, Bucharest, Romania.
Abstract:
Pathophysiological effects of infection with Gram-negative bacteria depend on recognition by host cells of LPS, a major component of the outer membrane of these microorganisms. CD14 is an immunological marker and also the receptor for LPS on phagocytic cells. The aim of the present study was to investigate the capacity of a bacterial immunomodulator, named Cantastim, which is used as a therapeutical agent in neoplasic diseases and chronic infections, to modulate the CD14 expression on human granulocytes. Our preliminary results showed that Cantastim can not influence the expression of CD14 on granulocytes obtained from healthy donors, but on the other hand Cantastim was able in vitro and in vivo to down-regulate the expression of this marker on granulocytes from a patient with neoplasic disease.
Insights
Cantastim, a bacterial immunomodulator, down-regulates CD14 expression on granulocytes in patients with neoplasic disease, but not in healthy donors. This finding impacts understanding of immune responses in cancer and chronic infections.
Area of Science:
- Immunology
- Microbiology
- Oncology
Background:
- Gram-negative bacterial infections involve lipopolysaccharide (LPS) recognition by host cells.
- CD14 serves as a key receptor for LPS on phagocytic cells, influencing immune responses.
- Bacterial immunomodulators like Cantastim are explored for therapeutic potential in cancer and chronic infections.
Purpose of the Study:
- To investigate Cantastim's capacity to modulate CD14 expression on human granulocytes.
- To determine if Cantastim affects CD14 levels in healthy individuals versus patients with neoplasic disease.
Main Methods:
- In vitro and in vivo studies were conducted.
- Human granulocytes from healthy donors and a patient with neoplasic disease were analyzed.
- CD14 expression levels were measured before and after Cantastim treatment.
Main Results:
- Cantastim did not influence CD14 expression on granulocytes from healthy donors.
- Cantastim demonstrated the ability to down-regulate CD14 expression on granulocytes from a patient with neoplasic disease.
- Both in vitro and in vivo experiments confirmed this down-regulatory effect in the patient.
Conclusions:
- Cantastim exhibits differential effects on CD14 expression based on the donor's health status.
- The down-regulation of CD14 by Cantastim in neoplasic disease warrants further investigation for therapeutic applications.
- Cantastim may play a role in modulating immune cell responses in the context of cancer.